Additional actionable alterations including mutations in the active site of isocitrate dehydrogenases (IDH1/2) and EGFR aberrations, e.g. gene amplification and deletion of exon 2-7 (EGFRvIII), have been shown to play an important role in oncogenesis and progression of glioma, and may carry important theranostic significance [7, 12] [13]. This evidence concerns the gene IDH1 and central nervous system cancer.